The John Innes Centre (JIC) seeks a creative junior or established researcher to set up and lead an internationally excellent, independent research programme in fundamental plant biology relevant to legumes or other rotation crops. The postholder is encouraged to address biological questions with clear relevance to UK agriculture.
The RESI Conference will be held on January 11-12 at the San Francisco Marriott Marquis, featuring two days in-person event followed by three days (January 13, 18 & 19) of online partnership activities. Previous RESI JPM conferences have drawn over a thousand attendees, including more than 600 early-stage life science investors, innovators, and industry experts. This RESI is held concurrently with JP Morgan Healthcare Week.
The apparent tectonic shift in the global bio-innovation landscape has markedly accelerated, and 2025-26 is providing One Nucleus members with exciting opportunities and huge challenges like never before. Adapting to maintain the key role of convener, supporter, ally and compass for members navigating these changes has led One Nucleus to invest in developing a new toolbox to help our members.
Tagomics is a Cambridge-based biotechnology company developing a next-generation multi-omic platform to transform how disease and drug safety are understood, measured and monitored.
Our proprietary technology extracts genetic, epigenetic and fragmentomic information from circulating cell-free DNA. Combined with advanced bioinformatics and machine learning, it enables deep biological insight across applications including drug safety, organ health monitoring and cancer detection.
🔹 Project Manager
🔹 Senior/Principal Assay Development Scientist (Genetic Code Expansion)
🔹 Research Associate (tRNA)
🔹 Lead Scientist (Novel Biomolecule Process Development)
PrecisionLife is helping transform the delivery of healthcare by building the next generation of precision medicine solutions and mechanostic® tests to improve disease detection, patient triage & outcomes, predict patients’ drug responses and reduce the cost of delivering effective care.
We’re a precision medicine company with global ambition and partnerships with some of the largest international healthcare companies and research institutes. We’re headquartered near Oxford, UK, with offices in London, Copenhagen, Warsaw and Boston, MA.
About Maxion
Amsbio has launched a range of synthetic cell mimic products that eliminate the variability, fragility, and operational inefficiency inherent in traditional flow cytometry biological and polystyrene bead controls.
Researchers in pharmaceutical companies, biotechnology firms, CRO’s, clinical diagnostics and academic centres have long sought access to mass-produced cell mimics that contain rare biomarkers and are stable over the long term for the development of targeted therapies.